Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CureVac’s German Owner Rejects US Coronavirus Vaccine Grab

Made In Germany For the World Is Hopp’s Vision

Executive Summary

Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.

You may also be interested in...



Coronavirus Update: Europe Enters Lockdown, Pharma Home Working, Belldegrun Tests Positive

Governments around Europe take action to shut places of work and schools and impose new border restrictions, as death toll rises in Italy, France and Spain.

Buying The Coronavirus Vaccine: What Would A ‘Fair And Reasonable’ Price Be?

The US government has a routine approach for negotiating single-seller/single-buyer contracts, but drug pricing politics and public fears of coronavirus will likely complicate any purchasing talks with a sponsor, should an effective vaccine or therapeutic emerge.

US Biopharma ‘Consortium’ Promises Array Of Coronavirus Remedies

Trump Administration officials pledge support for basic science and expedited regulatory review while emphasizing the benefits that could be offered by drugs in the near term until a vaccine is developed.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC141842

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel